Tag Archive for: Medtech

Weekly round-up: Ottimo Pharma Raises over $140 Million in Series A Financing 

Ottimo Pharma, a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, on Thursday announced the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and […]

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXessTM, its restorative vascular access conduit EINDHOVEN, The Netherlands, 5 November 2024 – Xeltis, a leading developer of transformative implants that enable the natural […]

Biocomposites acquires remaining shares in manufacturers of SYNICEM™ and Subiton products

SYNICEM™ and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers support surgeons’ infection treatment strategiesLaboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. are the manufacturers of SYNICEM™ and Subiton products Keele, UK, 18 September 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone […]

Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix® Spinal System

The Hague, Netherlands, 11 June 2024: Amber Implants (‘Amber’ or ‘the Company’), an innovative medical technology company developing next-generation implants for spinal injuries, today announces that it has completed enrolment of its first-in-human clinical trial with its innovative VCFix® Spinal System. The VCFix® Spinal System is the first device that does not rely on bone […]

Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium

Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel EINDHOVEN, The Netherlands, 17 April 2024 – Xeltis, […]